The global high-throughput screening market size is projected to reach USD 26.4 billion by 2025 from USD 15.3 billion in 2020, at a CAGR of 11.5% during the forecast period. The growth in this market is primarily attributed to increasing R&D spending by pharmaceutical & biotechnology companies, technological advancements in high-throughput screening market and the availability of government funding & venture capital investments. Emerging markets are expected to provide growth opportunities for players operating in the high-throughput screening market in the coming years. However, costly and time-consuming nature of HTS techniques and a serious shortage of skilled operators in the industry are the major challenge in this market.
The services segment accounted for the highest growth rate in the high-throughput screening market, by product & service, during the forecast period The high-throughput screening market is segmented into consumables, instruments, , services, and software.The services segment accounted for the highest growth rate in the high-throughput screening market in 2020.
This segment’s large share can be attributed to large pharmaceutical companies routinely engaging in outsourcing many tasks such as screening and lead identification, toxicology, and other preclinical studies.
Contract research organizations segment accounted for the highest CAGR Based on end user , the high-throughput screeningmarket is segmented into pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations (CROs) and other end users.In 2020, contract research organizations accounted for the highest growth rate.
The major factor driving the growth of this segment is increasing trend of outsourcing of R&D activities by pharmaceutical and biotechnology companies.
Label-free Technology segment accounted for the highest CAGR Based on technology , the high-throughput screeningmarket is segmented into cell-based assays, lab-on-a-chip technology, and label-free technology.In 2020, the label-free technology segment accounted for the highest growth rate.
Label-free technology provides a simple assessment technique for studying complex biological pathways as it does not involve the use of labels. This will support the growth of this technology segment in the HTS market during forecast period.
Drug Discovery segment accounted for the highest CAGR Based on application , the high-throughput screeningmarket is segmented into drug discovery, biochemical screening, life sciences research and other applications.In 2020, the drug discovery segment accounted for the highest growth rate.
The key factor driving this segment’s growth is the increasing number of clinical trials and rising pharmaceutical R&D expenditure.
Asia Pacific: The fastest-growing country in the high-throughput screening market The high-throughput screening market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW).Asia Pacific is projected to register the highest CAGR during the forecast period.
Factors such as the rising R&D spending, growing public-private partnerships, and increasing government funding are factors driving the growth of the HTS market in this region.
The primary interviews conducted for this report can be categorized as follows: • By Company Type: Tier 1 - 37%, Tier 2 - 22%, and Tier 3 - 41% • By Designation: C-level - 25%, D-level - 20%, and Others - 55% • By Region: North America -40%, Europe -27%, Asia-Pacific -20%, RoW -13%
Lists of Companies Profiled in the Report: • Thermo Fisher Scientific, Inc. (US) • Agilent Technologies, Inc. (US) • Merck KGaA (Germany) • Danaher Corporation (US) • PerkinElmer, Inc. (US) • Tecan Group Ltd. (Switzerland) • AXXAM S.p.A (Italy) • Promega Corporation (US) • Bio-Rad Laboratories, Inc.(US) • Promega Corporation (US) • Hamilton Company (US) • Corning Incorporated (US) • Charles River Laboratories (US) • Lonza (Switzerland) • REPROCELL Inc. (Japan) • Aurora Biomed (Canada) • BMG LABTECH (Germany) • DIANA Biotechnologies, s.r.o. (Czech Republic) • NanoTemper Technologies GmbH (Germany) • Creative Biolabs (US) • Biomat Srl (Italy)
Research Coverage: This report provides a detailed picture of the Immunofluorescence assay market.It aims at estimating the size and future growth potential of the market across different segments, such as the product, type, disease, end user, and region.
The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall high-throughput screening market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.
This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
Our reports have been used by over 10K customers, including:
The cell-based assays market is projected to reach USD 22.0 billion by 2025 from USD 14.9 billion in 2020, at a CAGR of 8.1% during the forecast period. The growing preference for cell-based assays in drug discovery, increasing funding for cell-based research, and growth in the number of drug discovery activities are the key factors supporting...
The Asia Pacific organoids market is expected to reach US$ 513.74 million in 2027 from US$ 97.02 million in 2019. The market is estimated to grow at a CAGR of 23.1% from 2020 to 2027. Rising adoption of biobanking and tumor modelling and alternatives for animal testing models acting as kingpins are expected to augment the growth of the...
The Europe organoids market is projected to reach US$ 1,260.08 million by 2027 from US$ 247.85 million in 2019; it is estimated to grow at a CAGR of 22.5% from 2020 to 2027. Increasing demand for tumor modelling and biobanking and rising adoption of personalized drugs are expected to drive the market. Personalized medicine is a growing...
The global in vivo toxicology market size is projected to reach USD 6.6 billion by 2025 from USD 5.0 billion in 2020, at a CAGR of 5.5% during the forecast period. Market growth is driven largely by the increasing pharmaceutical R&D activities, innovations in animal models, the development of exclusive in vivo toxicology tests, and the increasing...
The quantitative structure-activity relationship (QSAR) market is expected to reach US$ 1,888.5 million by 2027 from US$ 1,388.1 million in 2019; it is estimated to grow at a CAGR of 4.0% during 2020–2027. The market growth is mainly attributed to the increasing adoption rate of modeling tools in drug discovery and rising investments for drug...
176 pages •
By Global Industry Analysts
• Apr 2021
- Global Healthcare Contract Research Organization (CRO) Market to Reach $54.7 Billion by 2027
- Amid the COVID-19 crisis, the global market for Healthcare Contract Research Organization (CRO) estimated at US$38.4 Billion in the year 2020, is projected to reach a revised size of US$54.7 Billion by 2027,...
The Global Electronic Clinical Outcome Assessment Solution Market (eCOA) size is expected to reach $2.4 billion by 2026, rising at a market growth of 19% CAGR during the forecast period. Electronic clinical outcome assessment (eCOA) refers to a system that is capable of measuring mental state, patient symptom, and the prognosis of a disease....
An organ-on-a-chip is a microfluidic cell culture device that contains continuously perfused chambers. This chip develops a narrow channel for the blood and airflow in organs, such as the lung, gut, liver, heart, and other organs. Such devices produce multiple levels of tissue and organ functionalities, which are not feasible using conventional...
Certain factors that are driving the market growth include rising healthcare expenditure, growing burden of chronic diseases and advances in drug discovery and development. The burden of chronic diseases is increasing worldwide. According to WHO, chronic diseases have always been a massive global challenge, and they account for approximately...
The microplate reader market was valued at US$ 534.5 million in 2019 and is projected to reach US$ 704.4 million by 2027; it is expected to grow at a CAGR of 3.6% during 2020–2027. The market is attributed to increasing research and development in the pharmaceuticals industry, and escalating incidence of infectious diseases. However, high...
Research And Development
Infectious Disease Incidence
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.